- Home
- LEGH vs ORIC Comparison
LEGH vs ORIC Comparison
Compare LEGH & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- ORIC
- Stock Information
- Founded
- LEGH 2005
- ORIC 2014
- Country
- LEGH United States
- ORIC United States
- Employees
- LEGH N/A
- ORIC N/A
- Industry
- LEGH Homebuilding
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- ORIC Health Care
- Exchange
- LEGH Nasdaq
- ORIC Nasdaq
- Market Cap
- LEGH 588.8M
- ORIC 362.9M
- IPO Year
- LEGH 2018
- ORIC 2020
- Fundamental
- Price
- LEGH $23.97
- ORIC $10.50
- Analyst Decision
- LEGH Strong Buy
- ORIC Strong Buy
- Analyst Count
- LEGH 2
- ORIC 8
- Target Price
- LEGH $29.00
- ORIC $18.83
- AVG Volume (30 Days)
- LEGH 102.9K
- ORIC 1.1M
- Earning Date
- LEGH 08-07-2025
- ORIC 08-11-2025
- Dividend Yield
- LEGH N/A
- ORIC N/A
- EPS Growth
- LEGH 8.04
- ORIC N/A
- EPS
- LEGH 2.29
- ORIC N/A
- Revenue
- LEGH $176,618,000.00
- ORIC N/A
- Revenue This Year
- LEGH N/A
- ORIC N/A
- Revenue Next Year
- LEGH $8.23
- ORIC N/A
- P/E Ratio
- LEGH $10.47
- ORIC N/A
- Revenue Growth
- LEGH N/A
- ORIC N/A
- 52 Week Low
- LEGH $21.58
- ORIC $3.90
- 52 Week High
- LEGH $29.31
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- LEGH 63.30
- ORIC 70.83
- Support Level
- LEGH $21.91
- ORIC $9.80
- Resistance Level
- LEGH $24.17
- ORIC $11.19
- Average True Range (ATR)
- LEGH 0.61
- ORIC 0.61
- MACD
- LEGH 0.27
- ORIC -0.04
- Stochastic Oscillator
- LEGH 89.96
- ORIC 81.20
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.